Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
By C. Gibson, Roxana Mehran, Christoph Bode, J. Halperin, F. Verheugt, P. Wildgoose, Mary Birmingham, Juliana Ianus, P. Burton, Martin van Eickels and 7 more. New England Journal of Medicine, 2016
1,410 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/436b5a85f2347fccfec9768f6c1d24cffafa9736
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Jeroen J. Bax
- A. Goette
- Helmut Baumgartner
- Volkmar Falk
- Jose Luis Zamorano
- T. Anderson
- P. Lancellotti
- Gerhard Hindricks
Citations in the corpus
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. (2016, background): “Las pautas de tratamiento fueron seleccionadas en base a estudios previos, como el WOEST (AVK y clopidogrel), ATLAS ACS 2 TIMI 51 (rivaroxabán en SCA con dosis de 2,5 o 5 mg/12 horas) y ROCKET AF (15 mg/24 horas en 30% de los pacientes con deterioro de la función renal y utilizado en la vida real en”
- [2017 ESC/EACTS Guidelines for the management of valvular heart disease]. (2017, background): “Dual therapy comprising VKA and clopidogrel (75 mg/day) should be considered as an alternative to 1-month triple antithrombotic therapy in patients in whom the bleeding risk outweighs the ischaemic risk.(183,184) IIa A”
- 2018 ESC/EACTS Guidelines on myocardial revascularization. (2019, neutral): “apy in patients in whom the bleeding risk outweighs the ischaemic risk.(754,756,757) IIa A”
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2017, methodology): “) plus DAPT (95% clopidogrel) for 1, 6, or 12 months, or standard therapy with a dose-adjusted vitamin K antagonist plus DAPT (96% clopidogrel) for 1, 6, or 12 months.(272) The primary safety endpoint (TIMI clinically significant bleeding) was lower in the two groups receiving rivaroxaban.”